Merck Enters Organoid Field, Acquisition of HUB Organoids

On December 17 local time, MilliporeSigma, the life sciences business unit of German pharmaceutical and chemical giant Merck Group, announced that it would complete the acquisition of HUB Organoids, an internationally recognized pioneer in organoid research and development, by the end of 2024. This has undoubtedly created a huge stir in the organoid market.

Officials said that through this acquisition, Merck aims to expand its portfolio of 2D and 3D cell culture products. As the fastest - growing area in cell culture, organoids have the potential to accelerate drug development and reduce animal testing.

Jean - Charles Wirth, Head of Science and Laboratory Solutions at Merck Life Science, said, "For researchers committed to adopting new approaches to treat today's most challenging diseases, organoids provide important insights into biological systems. We look forward to enabling scientists to obtain solutions from samples more quickly and conveniently."

The application prospects of organoids will help Merck achieve its goals in sustainability, diversity, and inclusion. By using organoids, researchers may be able to reduce their reliance on animal testing by eliminating certain stages in the R & D process, which plays a positive role in promoting the search for more environmentally sustainable alternatives. Organoids also create opportunities to represent genetically diverse populations in research. They enable scientists to better understand drug interactions in patient groups that are under - represented in clinical trials.

Learn more: https://www.huborganoids.nl/news/merck-to-acquire-hub-organoids-holding-bv-advancing-next-generation-biology-portfolio/